Poolbeg Pharma PLC

Notice of POLB 001 Oncology Programme Update Meeting

By Elric Langton | 1 November 2023

I have a financial interest in Poolbeg Pharma.

Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors and analysts on the POLB 001 Oncology ProgrammeCytokine Release Syndrome (CRS), a critical concern associated with numerous cancer immunotherapy treatments, stands at the forefront of Poolbeg's ongoing research efforts. CRS can manifest severely, endangering lives and often necessitating intensive care support, such as mechanical ventilation. Addressing this challenge, Poolbeg Pharma, a clinical-stage biopharmaceutical company devoted to addressing diseases with significant unmet medical needs, is pleased to announce a dedicated meeting for investors and analysts. This gathering will delve deeper into the POLB 001 Oncology Programme, focusing on CRS.